Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.630
Day High0.680
Open:0.680
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
GlobeNewswire
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
GlobeNewswire
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
GlobeNewswire
Arch Biopartners Closes Non-Brokered Private Placement
GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
GlobeNewswire
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
GlobeNewswire
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
GlobeNewswire
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
GlobeNewswire
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
GlobeNewswire
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
INK Research
CEO buying at Arch Biopartners (ARCH)
Company Chart of ARCH
GlobeNewswire
Arch Biopartners Closes Non-Brokered Private Placement
GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
GlobeNewswire
Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia
GlobeNewswire
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
GlobeNewswire
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
Baystreet
Jobs Numbers Due in Canada Next Week
AI-generated - The Globe and Mail
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARCH)
GlobeNewswire
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Profile

Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.